Quantcast

Latest Sirolimus Stories

2011-02-10 01:13:50

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center. The findings were published in the latest New England Journal of Medicine. James C. Yao, M.D., associate professor in MD Anderson's Department of Gastrointestinal Medical...

2011-02-09 13:35:17

Coated stents superior to bare metal stents in reducing restenosis A systematic review of medical evidence has determined drug-eluting stents (DES) outperform bare metal stents (BMS) for revascularization of chronic total occlusions. Researchers found coated stents reduce restenosis and target revascularization, offering a safe approach with similar adverse events as BMS. Full findings are available in the February issue of Catheterization and Cardiovascular Interventions, a journal published...

2011-01-10 08:00:00

HONG KONG, Jan. 10, 2011 /PRNewswire/ -- Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention (published-ahead-of-print, August 2010). Known...

2011-01-07 18:39:03

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects. Resveratrol stimulates the expression of adiponectin, a hormone derived from cells that manufacture and store fat, the team found. Adiponectin has a wide range of beneficial effects on obesity-related medical complications, said senior...

2011-01-04 08:00:00

FT. LAUDERDALE, Fla., Jan. 4, 2011 /PRNewswire/ -- OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology. The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix. Incorporated into the matrix are antibodies or antibody fragments that allow for capture in...

2010-12-23 02:16:26

Whitehead Institute researchers have linked hyperactivity in the mechanistic target of rapamycin complex 1 (mTORC1) cellular pathway, to reduced ketone production, which is a well-defined physiological trait of aging in mice. Their results are reported in the December 23 edition of the journal Nature. "This is the first paper that genetically shows that the mTORC1 pathway in mammals affects an aging phenotype," says Whitehead Institute Member David Sabatini. "It provides us with a molecular...

2010-12-14 00:01:42

Today Insightra Medical, one of the fastest growing medical device companies announced the expansion of cardiology products by the addition of a line of Coronary Dilatation Balloons (CDB). Irvine, CA (PRWEB) December 12, 2010 Insightra Medical, Irvine, CA, is aggressively targeting three major sectors of the medical device market: Cardiovascular, General Surgery and Urogynecology. Key to Insightra's growth is the continual addition of new product ranges to offer a full compliment of...

2010-12-09 10:39:00

EAST HANOVER, N.J., Dec. 9, 2010 /PRNewswire/ -- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San...

2010-12-02 07:00:00

HONG KONG, Dec. 2, 2010 /PRNewswire/ -- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis. The cumulative rate of the study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year follow-up, was 12.4% in patients treated with a Genous Stent, a 30%...

2010-11-29 06:00:00

DURHAM, N.C., Nov. 29, 2010 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent(TM) Drug Eluting Coronary Stent System (MiStent DES). DESSOLVE I is a prospective, open-label,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'